P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

• K. H. M. Kuo,
• D. M. Layton,
• A. Lal,
• H. Al-Samkari,
• J. Bhatia,
• P. A. Kosinski,
• B. Tong,
• M. Lynch,
• K. Uhlig,
• E. P. Vichinsky

Affiliations

K. H. M. Kuo

1 Division of Hematology, University of Toronto, Toronto, ON, Canada

D. M. Layton

2 Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom

A. Lal

3 Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA

H. Al-Samkari

4 Massachusetts General Hospital, Harvard Medical School, Boston, MA

J. Bhatia

5 Agios Pharmaceuticals, Inc., Cambridge, MA, United States of America

P. A. Kosinski

5 Agios Pharmaceuticals, Inc., Cambridge, MA, United States of America

B. Tong

5 Agios Pharmaceuticals, Inc., Cambridge, MA, United States of America

M. Lynch

5 Agios Pharmaceuticals, Inc., Cambridge, MA, United States of America

K. Uhlig

5 Agios Pharmaceuticals, Inc., Cambridge, MA, United States of America

E. P. Vichinsky

3 Division of Hematology, UCSF Benioff Children’s Hospital Oakland, Oakland, CA